CLAIMS




10

- 1. A drug delivery composition comprising a HPMC capsule containing the drug and wherein the HPMC capsule is provided with a coating such that the drug is not released from the capsule in the stomach.
- 5 2. A drug delivery composition according to claim 1, wherein the HPMC capsule is provided with a coating such that the drug is predominately released from the capsule in the small intestine.
 - 3. A drug delivery composition according to claim 1, wherein the HPMC capsule is provided with a coating such that the drug is predominately released from the capsule in the colon and/or terminal ileum.
 - 4. A drug delivery composition according to claim 2 wherein the coating comprised a material which dissolves at a pH of 5.5 or above.
 - 5. A drug delivery composition according to claim 3 wherein the coating comprises a material which dissolves at a pH 7 or above.
- 15 6. A drug delivery composition according to claim 2 wherein the coating comprises cellulose acetate trimellitiate (CAT).
 - 7. A drug delivery composition according to claim 2 wherein the coating comprises hydroxypropylmethyl cellulose phthalate (HPMCP).
- 8. A drug delivery composition according to claim 2 wherein the coating comprises polyvinyl acetate phthalate (PVAP).
 - 9. A drug delivery composition according to claim 2 wherein the coating comprises shellac.
- 10. A drug delivery composition according to claim 2 wherein the coating comprises a copolymer of methacrylic acid and methylmethacrylate (Eudragit L®).
 - 11. A drug delivery composition according to claim 3 wherein the coating composition comprises a material which is redox-sensitive.

15

5



- 13. A drug delivery composition according to claim 3 wherein the coating composition comprises a material which is degraded by enzymes or bacteria present in the colon.
- 14. A drug delivery composition according to claim 3 wherein the coating composition comprises a copolymer of methacrylic acid and methylmethacrylate to which has been added during polymerisation the monomer methyl acrylate.
- 10 15. A drug delivery composition according to claim 3 wherein the coating composition comprises a cellulose ester.
 - 16. A drug delivery composition according to claim 3 wherein the coating composition comprises polyvinyl acetate phthalate.
 - 17. A drug delivery composition according to claim 2 wherein the coating is applied in the range 5-15mg per cm² of capsule surface.
 - 18. A drug delivery composition according to claim 3 wherein the coating is applied in the range 5-20mg per cm² of capsule surface.
 - 19. A drug delivery system according to claim 2 wherein the drug is one which is effective in the small intestine.
 - 20. A drug delivery system according to claim 1 wherein the drug is one which acts locally in the colon.
- 21. A drug delivery system according to claim 1 wherin the coating is applied separately to empty HPMC capsule body and cap.
- 22. A drug delivery system according to claim 21 wherein the HPMC capsule body is coated with an insoluble polymer and the cap is enteric or colonic coated.



10

15

- 23. A drug delivery system according to claim 22 wherein the water insoluble polymer is ethyl cellulose.
- 24. A drug delivery system according to claim 1 wherein two equal HPMC capsule halves are filled with a caplet.
- 5 25. A drug delivery system according to claim 24 wherein the coating is applied separately to equal empty HPMC capsule halves.
 - 26. A drug delivery system according to claim 24 wherein one half is enteric coated and the other halve is colonic coated.
 - 27. A drug delivery system according to claim 24 wherein one half is coated with an insoluble polymer and the other half is enteric or colonic coated.
 - 28. A drug delivery system according to claim 1 wherein the stomach resistant coating is applied to HPMC capsules having a first coating of a water soluble polyvinyl alcohol.
 - 29. A drug delivery system according to claim 1 wherein the HPMC capsule is coated with a film which is non-dissolving at pH < 3 to 4 and dissolving at pH > 5.5.
 - 30. A drug delivery system according to claim 1 wherein the HPMC content of the capsule shell is in the range of from 10 to 90 % by weight.
 - 31. A drug delivery system according to claim 1 wherein stomach resistant coating is applied to HPMC capsules having a sealing on the gap between capsule body and cap.

